Market cap
₹35 Cr
Revenue (TTM)
₹86 Cr
P/E Ratio
--
P/B Ratio
0.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹-12 Cr
-
ROE
-17.7 %
-
ROCE
-4.5 %
-
Industry P/E
30.79
-
EV/EBITDA
-72.2
-
Debt to Equity
1.3
-
Book Value
₹41.6
-
EPS
₹-9
-
Face value
10
-
Shares outstanding
13,058,287
10 Years Aggregate
CFO
₹49.69 Cr
EBITDA
₹149.67 Cr
Net Profit
₹44.69 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ANG Lifesciences
| -10.4 | 9.2 | 9.1 | -3.6 | -30.6 | -16.4 | -- |
|
BSE Healthcare
| 9.5 | 9.4 | 9.8 | 12.1 | 27.6 | 14.5 | 11.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
ANG Lifesciences
| -35.0 | -34.6 | -42.2 | -74.4 | 1,194.7 | 82.3 | 4.2 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ANG Lifesciences
|
26.5 | 34.6 | 86.2 | -11.8 | -10.0 | -19.1 | -- | 0.6 |
| 3,248.2 | 40,546.6 | 5,452.9 | 1,056.0 | 22.4 | 23.9 | 38.4 | 9.0 | |
| 8,695.5 | 21,719.0 | 2,177.5 | 200.9 | 11.3 | 26.5 | 108.1 | 26.1 | |
| 2,038.2 | 15,490.4 | 2,187.2 | 649.7 | 31.5 | 19 | 24.2 | 4.3 | |
| 1,781.8 | 10,892.9 | 1,196.4 | 149.4 | -- | 27.5 | 58.8 | 14.6 | |
| 1,336.2 | 18,531.3 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.9 | 5.1 | |
| 2,171.6 | 34,908.7 | 4,147.8 | 709.5 | 22.3 | 18.3 | 49.2 | 8.4 | |
| 4,785.4 | 21,859.4 | 2,519.7 | 722.4 | 33.6 | 18.8 | 30.3 | 5.2 | |
| 472.5 | 9,248.1 | 1,432.0 | 149.0 | 19.1 | 7.9 | 61.6 | 3.7 | |
| 1,153.6 | 10,633.5 | 4,858.7 | 574.1 | 14.9 | 19.7 | 19.1 | 3.4 |
Shareholding Pattern
View DetailsNews & Analysis
All News
Sigachi Industries IPO: Information analysis
6 min read•By Arul Selvan and Udhayaprakash
About ANG Lifesciences
Manufacture of allopathic pharmaceutical preparations
-
Incorporated
2006
-
Chairman
--
-
Managing Director
Rajesh Gupta
-
Headquarters
Amritsar, Punjab
-
Website
Looking for more details about ANG Lifesciences India Ltd.’s IPO? Explore our IPO Details page.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
FAQs for ANG Lifesciences
What is the current share price of ANG Lifesciences India Ltd Today?
The share price of ANG Lifesciences India Ltd is ₹26.49 (BSE) as of 19-May-2026 IST. ANG Lifesciences India Ltd has given a return of -30.56% in the last 3 years.
What is the current PB & PE ratio of ANG Lifesciences India Ltd?
Since, TTM earnings of ANG Lifesciences India Ltd is negative, P/E ratio is not available.
The P/B ratio of ANG Lifesciences India Ltd is 0.64 times as on 19-May-2026, a 86 discount to its peers’ median range of 4.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.46
|
|
2024
|
0.00
|
0.77
|
|
2023
|
0.00
|
1.15
|
|
2022
|
4.83
|
2.90
|
|
2021
|
2.45
|
1.08
|
What is the 52 Week High and Low of ANG Lifesciences India Ltd?
The 52-week high and low of ANG Lifesciences India Ltd are Rs 39.70 and Rs 17.63 as of 20-May-2026.
What is the market cap of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd has a market capitalisation of ₹ 35 Cr as on 19-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in ANG Lifesciences India Ltd?
Before investing in ANG Lifesciences India Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.